Compare BridgeBio Pharma Inc (BBIO) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Procter & Gamble Co — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Procter & Gamble Co trades at $146.37 (market cap $345.49B). The key difference: Procter & Gamble Co is far larger — about 21.2× BridgeBio Pharma Inc's market cap, and Procter & Gamble Co pays a 2.87% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | PG | |
|---|---|---|
Market Cap | $16.27B | $345.49B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $167.18 |
52-Week Low | $44.81 | $138.10 |
Enterprise Value | $17.82B | $370.97B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Procter & Gamble (PG) trades at $148.37, up 0.9% on the day, with a neutral technical signal and bullish moving averages. The stock shows stable revenue near $84.3 billion in 2025 and consistent earnings beats, with a net income margin of 19.16%. Recent news highlights its dividend reliability amid market volatility, while analyst consensus leans bullish with a $161.71 price target.
PG offers steady growth and income appeal, supported by strong cash flow and a 69-year dividend growth streak. Risks include premium valuation multiples and soft demand concerns. Upside depends on execution of supply chain efficiencies and sustained margin strength in a competitive consumer staples landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
